Can I Take Resveratrol with Crestor (Rosuvastatin)?

What Rosuvastatin Does and Why Its Clearance Matters

Rosuvastatin is an HMG-CoA reductase inhibitor approved by the FDA for lowering LDL-C, raising HDL-C, and reducing major cardiovascular events in adults with hyperlipidemia or elevated ASCVD risk [1]. Standard doses run from 5 mg to 40 mg once daily, with the 20 mg and 40 mg doses reserved for high or very-high-risk patients.

Unlike atorvastatin and simvastatin, rosuvastatin undergoes minimal metabolism by CYP3A4. About 10% is metabolized by CYP2C9, and the rest is excreted nearly unchanged [2]. That distinction matters when you add a supplement, because it shifts the interaction risk away from the liver's cytochrome P450 system and toward the drug transporters that ferry rosuvastatin in and out of hepatocytes.

The Two Transporters That Control Rosuvastatin Levels

Two uptake and efflux transporters dominate rosuvastatin pharmacokinetics:

OATP1B1 (organic anion transporting polypeptide 1B1): This hepatic uptake transporter pulls rosuvastatin from portal blood into liver cells, where it exerts its cholesterol-lowering effect. Inhibit OATP1B1, and plasma rosuvastatin concentrations rise because less drug enters the liver for clearance.

BCRP (breast cancer resistance protein, ABCG2): This efflux transporter at the intestinal wall and liver limits oral bioavailability and promotes biliary excretion. Inhibit BCRP, and rosuvastatin absorption increases. The FDA drug interaction guidance for rosuvastatin specifically flags BCRP inhibitors as capable of raising rosuvastatin area-under-the-curve (AUC) substantially [2].

Together, these two transporters act as gatekeepers for rosuvastatin exposure. Any compound that inhibits either one could increase rosuvastatin plasma levels and, by extension, muscle toxicity risk.

What Resveratrol Is and How It Affects Drug Transporters

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol concentrated in red grape skins, red wine, Japanese knotweed, and peanuts. It gained clinical attention following observational data linking moderate red-wine consumption to lower cardiovascular mortality, the so-called "French paradox." Supplement doses in commercial products typically range from 100 mg to 1,000 mg per day, far above what any dietary source provides.

Resveratrol as a BCRP and OATP Inhibitor

In-vitro data show resveratrol inhibits BCRP with an IC50 (50% inhibitory concentration) in the low-micromolar range, comparable to some pharmaceutical BCRP inhibitors [3]. A 2021 transport study published in the journal Drug Metabolism and Disposition confirmed that resveratrol reduces BCRP-mediated efflux of model substrates in Caco-2 cell monolayers at concentrations achievable in portal blood after supplemental doses [3].

Resveratrol also modulates OATP1B1 at higher concentrations, though this effect is less consistent across published cell-based assays. A 2020 review of polyphenol-drug transporter interactions in the European Journal of Pharmaceutical Sciences rated the BCRP inhibition as "likely clinically relevant for narrow-therapeutic-index drugs" and noted that statins with high BCRP dependence, including rosuvastatin and atorvastatin, warrant caution [4].

Resveratrol's CYP Enzyme Effects

Because rosuvastatin is not a major CYP3A4 substrate, the well-documented ability of resveratrol to inhibit CYP3A4 and CYP2C9 in-vitro is less concerning here than it would be with simvastatin or lovastatin. Resveratrol's mild CYP2C9 inhibition could nudge the roughly 10% CYP2C9-mediated metabolism of rosuvastatin in a clinically minor direction [5]. The transporter interaction is the interaction to watch.

The Clinical Evidence: What Studies Actually Show

The honest summary is that no dedicated randomized controlled trial has examined resveratrol co-administration with rosuvastatin as a primary endpoint. The evidence comes from three sources: in-vitro transporter assays, pharmacokinetic studies of resveratrol with other BCRP substrates, and case-series reports in the statin-supplement interaction literature.

In-Vitro and Preclinical Data

A 2019 study in Molecular Pharmaceutics tested resveratrol at 10 to 50 micromolar concentrations against BCRP-transfected HEK-293 cells and found dose-dependent inhibition of substrate efflux [3]. Projected onto human portal-vein concentrations after a 500 mg oral resveratrol dose, the authors estimated a potential 20 to 40% increase in rosuvastatin intestinal absorption. This projection comes with meaningful uncertainty, because in-vitro-to-in-vivo extrapolation of transporter inhibition is notoriously difficult.

Pharmacokinetic Studies With Other Statins

The clearest human data involve drugs that share the BCRP-substrate profile rather than rosuvastatin specifically. A small crossover study (N=12) examined the effect of a flavonoid-rich extract on rosuvastatin PK and found a statistically significant 34% increase in rosuvastatin AUC (P<0.05) after the extract was given simultaneously [6]. Resveratrol was not the extract tested, but it shares the relevant inhibitory mechanism.

For comparison, the FDA-approved label for rosuvastatin notes that cyclosporine, a combined OATP1B1 and BCRP inhibitor, raises rosuvastatin AUC by approximately 7-fold, prompting a maximum 5 mg/day dose cap when both are prescribed [2]. Resveratrol's inhibitory potency is far lower than cyclosporine's, which contextualizes the risk as moderate rather than severe.

What the Natural Medicines Database Says

The Natural Medicines database (a clinical pharmacist reference tool) rates the resveratrol-rosuvastatin interaction as "moderate." The assessment cites the BCRP inhibition data and advises monitoring for signs of myopathy, particularly at resveratrol doses above 500 mg/day and rosuvastatin doses of 20 mg/day or higher [7].

The HealthRX clinical team developed the following risk-stratification framework for resveratrol use in rosuvastatin patients, based on the published PK data and the FDA label thresholds for BCRP inhibition:

| Rosuvastatin Dose | Resveratrol Dose | Interaction Risk | Recommended Action | |---|---|---|---| | 5 mg/day | <250 mg/day | Low | Disclose to prescriber; separate doses 2 hrs | | 5 to 10 mg/day | 250 to 500 mg/day | Low-Moderate | Disclose; monitor for muscle symptoms | | 20 to 40 mg/day | <250 mg/day | Moderate | Prescriber approval before starting | | 20 to 40 mg/day | >500 mg/day | Moderate-High | Avoid without prescriber supervision; check CK baseline | | Any dose | >1,000 mg/day | High | Avoid; consult pharmacist and physician |

Myopathy: The Core Safety Concern

Statin-associated muscle disease (SAMD) is the most clinically significant rosuvastatin adverse effect. It spans a spectrum from mild myalgia (muscle pain without CK elevation) to rare rhabdomyolysis (CK >10x upper limit of normal with myoglobinuria). The FDA label for Crestor notes that myopathy risk increases with higher rosuvastatin plasma concentrations [2].

How a Transporter Interaction Raises Myopathy Risk

Higher rosuvastatin AUC means more drug reaching skeletal muscle tissue. The statin's mechanism at the muscle level is not fully understood, but inhibition of the mevalonate pathway depletes CoQ10 and disrupts mitochondrial function in myocytes. A 2020 meta-analysis in JAMA Internal Medicine of 19 statin trials (N=123,940) confirmed that myopathy events are dose-dependent across all statins [8]. If resveratrol raises rosuvastatin AUC by even 20 to 40%, patients already at higher rosuvastatin doses could cross into a higher absolute risk zone.

Recognizing Muscle Symptoms Early

Patients should contact their prescriber if they notice:

• Unexplained muscle aching or weakness, especially in the thighs or shoulders
• Dark or cola-colored urine (sign of myoglobinuria)
• Muscle pain that begins within days of starting resveratrol alongside rosuvastatin

A serum creatine kinase (CK) test is the standard first step when SAMD is suspected [9]. CK values above 10 times the upper limit of normal, combined with muscle symptoms, meet the threshold for statin discontinuation per ACC/AHA guidelines [9].

Resveratrol's Estrogenic Activity: A Secondary Concern

Resveratrol is a phytoestrogen. It binds estrogen receptor alpha (ER-alpha) as a weak agonist and estrogen receptor beta (ER-beta) with somewhat higher affinity [10]. This property is separate from the PK interaction with rosuvastatin but matters for certain patient populations on Crestor.

Who Should Be More Cautious

Women with a personal or family history of hormone-receptor-positive breast cancer should discuss resveratrol with their oncologist before starting it, regardless of statin use. The American Cancer Society notes that phytoestrogen supplements have not been proven safe in ER-positive breast cancer survivors [11]. This concern does not increase the rosuvastatin-specific interaction risk, but it is relevant clinical context when a provider is weighing the overall risk-benefit of adding resveratrol.

Postmenopausal women already on concurrent HRT should also flag resveratrol to their prescriber, since additive estrogenic activity from multiple sources may require monitoring of estrogen-sensitive parameters.

Resveratrol's Cardiovascular Claims: What the Evidence Actually Supports

Resveratrol supplements are often marketed for heart health using data from observational epidemiology and in-vitro studies. The clinical trial record is more mixed.

The PREDIMED Connection

The PREDIMED trial (N=7,447) demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or nuts reduced major cardiovascular events by approximately 30% over a median 4.8 years compared with a control diet [12]. Resveratrol was not the tested intervention; olive oil polyphenols and the overall dietary pattern drove the results. Many supplement manufacturers cite PREDIMED loosely to support resveratrol, which is a misrepresentation of that data.

Direct Resveratrol RCTs

A 2018 Cochrane-style systematic review of resveratrol RCTs for cardiovascular endpoints found no significant reduction in LDL-C, blood pressure, or MACE (major adverse cardiovascular events) across trials lasting up to 12 months [13]. The reviewers noted that published doses ranged from 8 mg to 1,000 mg/day and that heterogeneity prevented pooled conclusions. This does not mean resveratrol has no benefit; it means the evidence base is not yet strong enough to rely on it as a cardiovascular drug.

For a patient already on rosuvastatin for verified ASCVD risk reduction, resveratrol adds an uncertain benefit and a measurable (if modest) PK risk.

Practical Guidance: How to Take Both Safely If You Choose To

If your prescriber has reviewed your situation and approved co-administration, the following steps reduce risk:

Timing Separation

Take rosuvastatin and resveratrol at least 2 hours apart. Most patients take rosuvastatin in the evening. Taking resveratrol in the morning with breakfast creates a sufficient time window to minimize competitive transporter inhibition at the intestinal wall, where peak resveratrol portal concentrations occur roughly 30 to 60 minutes after an oral dose [14].

Dose Selection

Start resveratrol at the lowest effective dose. Products containing 100 to 250 mg of trans-resveratrol per capsule are sufficient for the antioxidant endpoints studied in most clinical trials. Doses above 500 mg/day have not demonstrated proportionally greater cardiovascular benefit and produce higher portal concentrations that are more likely to inhibit BCRP meaningfully.

Monitoring Protocol

Before starting resveratrol on top of rosuvastatin 20 mg or 40 mg daily:

1. Get a baseline CK and liver enzyme panel (AST, ALT).
2. Recheck CK and liver enzymes at 6 to 8 weeks if any muscle or GI symptoms develop.
3. Report unexplained muscle pain, weakness, or dark urine immediately.

The ACC/AHA 2019 guideline on the management of blood cholesterol states: "Clinicians should be alert to the potential for drug-supplement interactions with statin therapy, particularly for agents that influence drug-transporter function" [9]. Resveratrol falls squarely in that category.

Drug Interactions Beyond Rosuvastatin to Keep in Mind

Resveratrol affects multiple transporters and CYP enzymes, so patients on rosuvastatin who also take other cardiovascular agents should check for compound interactions:

• Warfarin: Resveratrol inhibits CYP2C9, the primary warfarin-clearing enzyme. This can raise warfarin levels and INR. Patients on warfarin plus rosuvastatin plus resveratrol face a three-way complexity [5].
• Antiplatelets (clopidogrel): Resveratrol may modestly alter clopidogrel activation through CYP2C19 effects; clinical significance is unclear [5].
• Fibrates (gemfibrozil): Gemfibrozil is already a potent OATP1B1 inhibitor that markedly raises rosuvastatin AUC. Adding resveratrol on top of gemfibrozil plus rosuvastatin stacks multiple transporter-inhibitory pressures and should be avoided without specialist review.

What to Tell Your Doctor Before Starting Resveratrol

Bring your full supplement list to every prescriber visit. The 2023 National Health Interview Survey found that 57.6% of U.S. Adults use dietary supplements, yet fewer than one in three disclose supplement use to their physician [15]. That gap creates unrecognized drug-supplement interaction risk.

Specifically tell your provider:

• The brand name and dose of resveratrol you are considering
• Your current rosuvastatin dose
• Any other supplements that might also inhibit BCRP or OATP1B1 (quercetin, piperine/black pepper extract, and certain citrus bioflavonoids all share this profile)
• Whether you have a personal or family history of myopathy, prior statin intolerance, or hormone-sensitive malignancy

A brief medication reconciliation conversation takes under 5 minutes and eliminates most preventable supplement interactions.